How effective is Sinovac vaccine based on Brazil trials?

Question

Accepted Answer

Sinovac Vaccine Efficacy Rate in Brazil Trials

Based on clinical trials conducted in Brazil, the Sinovac vaccine demonstrated an efficacy rate of 50.4 per cent in preventing symptomatic infections. This figure was released by Brazil, impacting discussions around the vaccine's procurement by other nations.
Efficacy Findings from Brazil

Clinical trials in Brazil indicated that the Sinovac vaccine was 50.4% effective in preventing symptomatic Covid-19 infections. This specific efficacy rate has been a focal point in the evaluation of the vaccine by various countries.
Malaysian Regulatory Review Process

Malaysia's Science, Technology and Innovation Minister, Khairy Jamaluddin, stated that the country will thoroughly review Sinovac's clinical data. This review is a prerequisite to any procurement decision, ensuring that the vaccine meets Malaysia's safety and efficacy standards.
Broader Vaccine Procurement Context

The efficacy findings from Brazil emerged as Indonesia commenced its vaccination campaign using the Sinovac vaccine. Malaysia is simultaneously negotiating with other vaccine manufacturers, including CanSino Biologics from China and Russia's Gamaleya Institute, aiming to secure a diverse supply of Covid-19 vaccines. This includes additional vaccine doses from Pfizer-BioNTech and AstraZeneca.

Reading history

Hide →

This history is cleared when the page is closed.

How effective is Sinovac vaccine based on Brazil trials?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends